secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2022-12-30T23:59:59+00:00
Accession:  0001558370-22-019046
Event type: litigation
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01, 99.1
LLM model:  deepseek-v4-flash:cloud@v2

Aytu settles derivative lawsuits over 2021 option grants; cancels 25% of awards, adds independent directors
--------------------------------------------------------------------------------

- Settlement cancels 387,804 of 1,551,216 shares (25%) from 2021 option grants to directors and officers.
- Company to add two independent directors within six months; one appointed as Compensation Committee chair.
- Non-employee director compensation capped at $175,000 annually through 2024; new equity plan with reserve ≤15% of outstanding.
- No further equity awards to defendants under 2015 plan; lead independent director to be designated.
- Aytu to pay up to $425,000 in attorneys' fees; no admission of wrongdoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837022019046/0001558370-22-019046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837022019046/aytu-20221228x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-019046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer